<DOC>
	<DOCNO>NCT02832648</DOCNO>
	<brief_summary>This research aim determine whether selenium supplement improve bone muscle health old woman risk osteoporosis ( low bone density weak bone ) fracture ( broken bone ) . Osteoporosis major public health problem . One two woman one five men age 50 fracture . Fractures cause pain , disability reduce life-expectancy . Women below-average bone density around time menopause might previously take hormone replacement ( HRT ) prevent osteoporosis , HRT much less used due side effect . Therefore need safe , effective inexpensive preventative intervention woman risk osteoporosis . Selenium chemical nutrient present several human protein , include anti-oxidants . Anti-oxidants may protect age tissue , include bone , mop damage reactive oxygen molecule ( sometimes call 'free radical ' ) . Selenium present soil , obtain many food . However , soil selenium level low Europe , dietary intake UK recommend level . We previously find woman higher blood selenium level strong bone , n't prove give selenium improve bone strength . The investigator propose randomise controlled trial compare selenium supplement placebo ( dummy treatment ) woman below-average bone density . The investigator give selenium ( two different dos ) placebo 120 woman six month use blood urine test bone density scan see give selenium effect bone . The investigator also muscle function test measurement free radical molecule .</brief_summary>
	<brief_title>Selenium Musculoskeletal Health</brief_title>
	<detailed_description>This double-blind , randomise , placebo control trial . We evaluate two dos selenium ( 50 200mcg ) v placebo six month . Participants postmenopausal woman osteopenia osteoporosis ( T-score -1.0 -3.0 ) . The investigator include participant baseline serum selenium concentration generalisability , primary endpoint efficacy analysis include woman baseline serum selenium 120 mcg/l . Primary endpoint : Urinary N-telopeptide type I collagen ( NTX/Cr ) . Secondary endpoint : bone turnover marker , BMD , muscle function , thyroid function , blood glucose , anti-oxidant activity , inflammatory marker The investigator make primary analysis base woman baseline serum selenium 120 mcg/l . To ensure adequate power analysis plan recruit 120 woman ( expect 100 120 serum selenium 120 mcg/l base previous cross-sectional study ) . The investigator review baseline serum selenium result 40 woman recruit confirm expect distribution baseline level , adjust total recruitment number accordingly ensure least 99 woman serum selenium 120mcg/l randomise final primary endpoint intention-to-treat analysis . Participants randomise accord schedule produce Sheffield Teaching Hospitals pharmacy accord standard operating procedure . Randomisation carry independently study investigator use block randomisation . The blind broken judge PI clinically necessary wellbeing participant . The study may stop early investigator , sponsor DMEC identify safety concern . Trial management do Academic Unit Bone Metabolism CTIMP group ( meet monthly ) , progress report AUBM management group Lay Panel . We establish TSC DMEC .</detailed_description>
	<mesh_term>Osteoporosis</mesh_term>
	<mesh_term>Selenium</mesh_term>
	<criteria>woman age 55y least 5y postemenopausal willing able give inform consent lumbar spine total hip BMD Tscore 1.0 3.0 clinically require treatment osteoporosis diabetes mellitus , thyroid dysfunction , condition know affect bone metabolism ( inflammatory disease , parathyroid disease , malabsorption ) , medication know affect bone metabolism ( osteoporosis treatment , aromatase inhibitor , antiepileptic ) , alcohol intake &gt; 21 unit per week , prolong immobility ( &gt; 3 month ) , fracture last year , take selenium supplement last year</criteria>
	<gender>Female</gender>
	<minimum_age>55 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
</DOC>